Form 4: CRISPR Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Ali Behbahani, a Director of CRISPR Therapeutics AG, sold 13,679 shares of common stock on September 17, 2026 for $57.09 per share.
Summary
- Option exercise/conversion: acquired 30,000 Common Shares at $14.00 ($420,000) on September 17, 2026; holds 30,316 after (Direct).
- Open-market sale: disposed of 13,679 Common Shares at $57.09 ($780,935) on September 17, 2026; holds 16,637 after (Direct).
- Option exercise/conversion: disposed of 30,000 Stock Option (Right to Buy) on September 17, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $780,935 of stock on the open market.
Insider Transactions
Ali Behbahani — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Shares | 30,000 | $14 | $420.0K | 30,316 |
| 2026-09-17 | Open-market sale | Common Shares | 13,679 | $57 | $780.9K | 16,637 |
| 2026-09-17 | Option exercise/conversion | Stock Option (Right to Buy) | 30,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (30,000 shares) |
| 2026-09-17 | Open-market sale (13,679 shares) |
| 2026-09-17 | Option exercise/conversion (30,000 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, bearish, Ali Behbahani
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.